| Diabetes Mellitus
Admelog vs Afrezza - (Insulin Human) Inhalation Powder
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Admelog vs Afrezza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAfrezza has a higher rate of injection site reactions vs Admelog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Afrezza but not Admelog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Admelog
Afrezza
At A Glance
Subcutaneous, Continuous subcutaneous infusion (pump), Intravenous
Within 15 minutes before or immediately after meals
Rapid-acting insulin analog
Oral inhalation
At each meal
Rapid-acting insulin
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Individualize dose based on route of administration, metabolic needs, blood glucose monitoring, and glycemic control goal. Subcutaneous injection: Administer within 15 minutes before or immediately after a meal into abdominal wall, thigh, upper arm, or buttocks. Continuous subcutaneous infusion (insulin pump): Administer via pump in accordance with pump instructions; change reservoir at least every 7 days. Intravenous infusion: Administer only after dilution (0.1-1 unit/mL in 0.9% Sodium Chloride) under medical supervision. Rotate injection/infusion sites to reduce lipodystrophy risk.
Diabetes Mellitus Insulin-naive patients: 4 units inhaled at the beginning of each meal; patients switching from subcutaneous mealtime insulin convert per table (up to 3 units -> 4 units, 4-5 units -> 8 units, 6-7 units -> 12 units, >=8 units -> 16 units); adjust dose based on metabolic needs, blood glucose monitoring, and glycemic control goal.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro or any excipient in ADMELOG
- Episodes of hypoglycemia
- Chronic lung disease such as asthma or COPD due to risk of acute bronchospasm
- Previous severe hypersensitivity reaction to any regular human insulin product or any inactive ingredient in AFREZZA
Adverse Reactions
Most common (>=5%) Nasopharyngitis (13%), upper respiratory tract infection (6%).
Severe hypoglycemia 13.5% in type 1 diabetes (52 weeks), 2.4% in type 2 diabetes (26 weeks).
Postmarketing Medication errors with accidental insulin substitution, localized cutaneous amyloidosis at injection site.
Most common (>=2%) Cough, throat pain or irritation, headache, diarrhea, productive cough, fatigue, nausea
Serious Acute bronchospasm, hypoglycemia, decline in pulmonary function, lung cancer, diabetic ketoacidosis, hypersensitivity reactions
Postmarketing Bronchospasm
Pharmacology
Insulin lispro is a rapid-acting insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake by skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Insulin lowers blood glucose in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production; it also inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Admelog
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Afrezza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Admelog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Afrezza
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Admelog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Afrezza
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Admelog.
$99/momo
Afrezza Patient Direct ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdmelogView full Admelog profile
AfrezzaView full Afrezza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.